UB Paderborn / Katalog / Suche / in CDI

1 – 13 von 13

Sortiert nach

Vardenafil Improves Ejaculation Success Rates and Self-confidence in Men With Erectile Dysfunction due to Spinal Cord Injury

Spine (Philadelphia, Pa. 1976), 2008-04, Vol.33 (7), p.709-715

2008

Volltextzugriff (PDF)

Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

The Journal of urology, 2007-04, Vol.177 (4), p.1401-1407

2007

Volltextzugriff (PDF)

AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2)

Neurourology and urodynamics, 2023-01, Vol.42 (1), p.153-167

2023

Volltextzugriff (PDF)

Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement

World journal of urology, 2018-05, Vol.36 (5), p.801-809

2018

Volltextzugriff (PDF)

Long‐term results of treatment for prostate carcinoma by staging pelvic lymph node dissection and definitive irradiation using low‐dose rate temporary iridium‐192 interstitial implant and external beam radiotherapy

Cancer, 2001-10, Vol.92 (8), p.2084-2094

2001

Volltextzugriff (PDF)

Long‐term therapy with the dual 5α‐reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia

BJU international, 2006-01, Vol.97 (1), p.73-80

2006

Volltextzugriff (PDF)

A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer

Clinical therapeutics, 2002-11, Vol.24 (11), p.1902-1914

2002

Volltextzugriff (PDF)

Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia

BJU international, 2006-01, Vol.97 (1), p.73

2006

Volltextzugriff (PDF)

1636: The Efficacy and Safety of Tadalafil Administered Once a Day for Lower Urinary Tract Symptoms (LUTS) in Men with Benign Prostatic Hyperplasia (BPH)

The Journal of urology, 2006-04, Vol.175 (4), p.527-527

2006

Volltextzugriff (PDF)

Temporary iridium‐192 implant in the management of carcinoma of the prostate

Cancer, 1992-05, Vol.69 (10), p.2515-2524

1992

Volltextzugriff (PDF)

Male Permanent Contraception: Vasectomy

The Handbook of Contraception, p.255-272

Volltextzugriff (PDF)

Malignant Melanoma of the Renal Pelvis Presenting as a Primary Tumor

The Journal of urology, 1988-10, Vol.140 (4), p.812-814

1988

Volltextzugriff (PDF)

Ranking the risk of animal-to-human spillover for newly discovered viruses

Proceedings of the National Academy of Sciences - PNAS, 2021-04, Vol.118 (15), p.e2002324118

2021

Volltextzugriff (PDF)

1 – 13 von 13

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(12)
Mit Volltextzugriff
(10)

Publikationsform

Artikel
(12)
Buchkapitel
(1)

Sprache

Englisch
(13)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Vardenafil Improves Ejaculation Success Rates and Self-confidence in Men With Erectile Dysfunction due to Spinal Cord Injury

Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2)

Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement

Long‐term results of treatment for prostate carcinoma by staging pelvic lymph node dissection and definitive irradiation using low‐dose rate temporary iridium‐192 interstitial implant and external beam radiotherapy

Long‐term therapy with the dual 5α‐reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia

A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer

Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia

1636: The Efficacy and Safety of Tadalafil Administered Once a Day for Lower Urinary Tract Symptoms (LUTS) in Men with Benign Prostatic Hyperplasia (BPH)

Temporary iridium‐192 implant in the management of carcinoma of the prostate

Male Permanent Contraception: Vasectomy

Malignant Melanoma of the Renal Pelvis Presenting as a Primary Tumor

Ranking the risk of animal-to-human spillover for newly discovered viruses

Suchergebnisse filtern